Literature DB >> 28965713

Predictors of 1-Year Mortality After Transcatheter Aortic Valve Implantation in Patients With and Without Advanced Chronic Kidney Disease.

Amos Levi1, Pablo Codner1, Amer Masalha1, Giuseppe Gargiulo2, Fabien Praz3, Kentaro Hayashida4, Yusuke Watanabe5, Darren Mylotte6, Nicolas Debry7, Marco Barbanti8, Thierry Lefèvre8, Thomas Modine7, Johan Bosmans9, Stephan Windecker3, Israel Barbash10, Jan-Malte Sinning11, Georg Nickenig11, Alon Barsheshet1, Ran Kornowski12.   

Abstract

Advanced chronic kidney disease (CKD) is an independent predictor of mortality in patients undergoing transcatheter aortic valve implantation (TAVI). We aimed to identify predictors of 1-year mortality in patients after TAVI stratified by the presence or absence of advanced CKD (defined as estimated glomerular filtration rate ≤30 ml/min/1.73 m2 or permanent renal replacement therapy). Patients (n = 1204) from 10 centers in Europe, Japan, and Israel were included: 464 with and 740 without advanced CKD. Advanced CKD was associated with a 2-fold increase in the adjusted risk of 1-year all-cause death (p <0.001), and a 1.9-fold increase in cardiovascular death (p = 0.016). Interaction-term analysis was used to identify and compare independent predictors of 1-year mortality in both groups. Impaired left ventricular ejection fraction and poor functional class were predictive of death in the advanced CKD group (odds ratio [OR] 2.27, p = 0.002 and OR 3.87, p = 0.003, respectively) but not in patients without advanced CKD (p for interaction = 0.035 and 0.039, respectively), whereas bleeding was a predictor of mortality in the nonadvanced CKD group (OR 3.2, p = 0.005) but not in advanced CKD (p for interaction = 0.006). Atrial fibrillation was associated with a 2.2-fold increase (p = 0.032) in the risk of cardiovascular death in the advanced CKD group but not in the absence of advanced CKD (p for interaction = 0.022). In conclusion, the coexistence of advanced CKD and either reduced left ventricular ejection fraction or poor functional class has an incremental effect on the risk of death after TAVI. In contrast, bleeding had a greater effect on risk of death in patients without advanced CKD.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28965713     DOI: 10.1016/j.amjcard.2017.08.020

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Transcatheter aortic valve implantation facilitated by right common carotid cut-down and innominate artery angioplasty with simultaneous right coronary artery vein graft percutaneous coronary intervention in a patient with mid aortic syndrome: a case report.

Authors:  Mina S A Ghobrial; Kamal Khan; Mohamed Baguneid; Richard D Levy
Journal:  Eur Heart J Case Rep       Date:  2020-05-26

2.  Trends in Readmission and Costs After Transcatheter Implantation Versus Surgical Aortic Valve Replacement in Patients With Renal Dysfunction.

Authors:  Yas Sanaiha; Aditya Mantha; Boback Ziaeian; Yen-Yi Juo; Richard J Shemin; Peyman Benharash
Journal:  Am J Cardiol       Date:  2019-02-08       Impact factor: 2.778

3.  Paradoxical low-flow aortic stenosis - baseline characteristics, impact on mortality.

Authors:  Karol Zbroński; Zenon Huczek; Monika Gawalko; Agata Ćwiek; Bartosz Rymuza; Kajetan Grodecki; Piotr Scisło; Radosław Wilimski; Janusz Kochman; Krzysztof J Filipiak; Grzegorz Opolski
Journal:  Postepy Kardiol Interwencyjnej       Date:  2019-04-04       Impact factor: 1.426

Review 4.  Valvular Heart Disease in Patients with Chronic Kidney Disease.

Authors:  Konstantina Kipourou; Jamie M O'Driscoll; Rajan Sharma
Journal:  Eur Cardiol       Date:  2022-01-31

5.  Impact of Transcatheter Aortic Valve Implantation on Kidney Function.

Authors:  Rita Calça; Rui C Teles; Patrícia Branco; Augusta Gaspar; João Brito; Tiago Nolasco; Manuel D Almeida; José P Neves; Miguel Mendes; Domingos S Machado; André Weigert
Journal:  Arq Bras Cardiol       Date:  2019-12       Impact factor: 2.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.